CardioQ update

Deltex Medical Group PLC
26 March 2008





                            Deltex Medical Group plc

       CardioQ shown to halve average recovery times after major surgery


26 March 2008 - Deltex Medical Group plc ('Deltex Medical'), the UK's leading
haemodynamic monitoring company, notes results from introducing a new approach
to major surgery that includes routine use of the CardioQ.

The article published in the March edition of Health Director, reports on a
study led by Mr Mike Parker, a senior consultant colorectal surgeon at Darent
Valley hospital in Kent and current President of the Association of Laparoscopic
Surgeons of Great Britain and Ireland. The study reports on the impact of
introducing combination of an enhanced recovery programme (including oesophageal
Doppler monitoring with the CardioQ) and minimally invasive surgical techniques
('laparoscopic' or 'keyhole' surgery) for patients undergoing major bowel
surgery.

Conducted between January 2003 and June 2007, the study, monitored the time
patients spent in hospital and the time until they reported themselves feeling
fully recovered (i.e. as well as they had felt before their operation). Data
recorded for 200 patients having laparoscopic surgery under the enhanced
recovery programme was compared to that for patients having open surgery under
traditional care pathways in the same hospital.

The study found that the average enhanced recovery laparoscopic patient left
hospital after five days and was fully recovered after a further seven days, a
total recovery time of 12 days. By contrast, the average patient receiving
traditional care (open surgery, no CardioQ, no enhanced recovery programme) left
hospital after eleven days and was only fully recovered after another 29 days, a
total recovery time of 40 days.


Mr Parker stated:

'By enabling patients to leave hospital sooner and recover more quickly we are
saving the (NHS) trust a significant amount of money. For the third of patients
we treated who were returning to work we also saved the economy substantial sums
by enabling them to return to work a full three weeks earlier than before.'


Deltex Medical's Chief Executive, Andy Hill commented:

'The combination of enhanced recovery programmes, keyhole surgery and the
CardioQ is extremely powerful and this data will be of interest to doctors,
patients, healthcare providers and health insurers in most developed healthcare
systems, including the in the USA.'



For further information, please contact:-

Deltex Medical Group plc                        01243 774 837
Nigel Keen, Chairman                            [e-mail]
Andy Hill, Chief Executive                      [e-mail]
Ewan Phillips, Finance Director                 [e-mail]

Gavin Anderson & Company                        0207 554 1400
Deborah Walter                                  [e-mail]
Robert Speed                                    [e-mail]

Charles Stanley Securities                      020 7149 6000
Philip Davies                                   [e-mail]
Russell Cook                                    [e-mail]



Notes for Editors

Deltex Medical manufactures and markets the CardioQ(TM) monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already around 1,500 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.




                      This information is provided by RNS
            The company news service from the London Stock Exchange